AstraZeneca Pharma India Ltd

NSE: ASTRAZEN · BSE: 506820 · Pharmaceuticals & Biotechnology · 52 announcements

Share price: ₹6,507.00
Market cap: ₹16,268 Cr
Revenue (annual): ₹2,276 Cr
Net profit (annual): ₹187.5 Cr
P/E (TTM): 91.5×Sector 43.8×
Promoter holding: 75.00%+0.00% QoQ
FII holding: 2.64%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

Announcement type

All Management Change 8 Legal & Regulatory 8 Other Announcement 7 Regulatory Approval 6 Annual General Meeting 5 Financial Results 4 Results Update 3 Board Meeting Date 3 Dividend 2 Capacity Expansion 2 Product Launch 1 Business Update 1 Annual Report 1 Adverse Business Impact 1

Time

All time Last 1 week Last 1 month Last 2 months Last 3 months Last 6 months Last 1 year

1 announcement with these filters

7 Nov 2026 12:19 IST BSE

Product Launch

AstraZeneca Pharma India Product Launch

AstraZeneca Pharma India will launch Datverzo, Datopotamab Deruxtecan, in India in November 2026. The drug holds DCGI import and market permission for HR-positive, HER2-negative breast cancer.

Open announcement → Read the filing ↗